Emergent BioSolutions is a specialty life‑sciences company that develops, manufactures, and distributes medical countermeasures for public‑health emergencies, including FDA‑approved vaccines such as ACAM2000® for smallpox and mpox and opioid overdose treatments like NARCAN® nasal spray. It also provides contract manufacturing and process‑development services to accelerate biologic production for government agencies and biopharma partners, leveraging a global supply network to deliver critical protective products quickly and reliably.
Funding
$250M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Public health systems often lack rapid access to approved vaccines, antidotes, and manufacturing capacity needed to respond to emerging infectious diseases, biothreats, and opioid overdoses, leading to delayed protection and higher mortality.
Solution
Emergent BioSolutions operates as a specialty life‑sciences company that develops, manufactures, and distributes medical countermeasures for public health emergencies. The company supplies licensed vaccines such as ACAM2000® for smallpox and mpox, and life‑saving opioid overdose treatments like NARCAN® nasal spray. It also offers contract manufacturing and process‑development services to accelerate the production of biologics, exemplified by its partnership with SAB Biotherapeutics on a type 1 diabetes candidate. By maintaining FDA‑approved facilities and a global supply network, Emergent enables governments and health agencies to obtain critical protective products quickly and reliably.
Target Audience
Primary customers are government health agencies, public‑health preparedness programs, and biopharma companies seeking manufacturing and development support for vaccines and therapeutic biologics.
Features
- FDA‑approved live vaccinia vaccine (ACAM2000®) with expanded indication for mpox prevention
- NARCAN® nasal spray for rapid opioid overdose reversal, supported by public awareness campaigns
- Full‑scale contract manufacturing and process development for biologics, including a multi‑year agreement for a type 1 diabetes therapeutic
- Global distribution infrastructure ensuring rapid delivery of countermeasures to national stockpiles and health organizations
- Integrated public‑health outreach tools such as the Opioid Crisis Impact Map to educate communities and reduce stigma